Thanes Vanig, MD
Infectious Disease · Phoenix, AZNPI 1215925441
Payments from drug & device makers
Across 691 payments — averaging $682.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$280K
- Viiv Healthcare Company$131K
- Janssen Products, LP$44K
- Merck$13K
- Janssen Scientific Affairs, LLC$839
- Johnson & Johnson$695
- plus $2K from 18 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 348 | $279,912 |
| Viiv Healthcare Company | 114 | $131,327 |
| Janssen Products, LP | 45 | $44,473 |
| Merck | 46 | $12,519 |
| Janssen Scientific Affairs, LLC | 2 | $839 |
| Johnson & Johnson(2 entities) | 48 | $695 |
| Pfizer | 36 | $537 |
| AbbVie(2 entities) | 12 | $244 |
| Theratechnologies Inc. | 10 | $189 |
| Hologic Sales And Service, LLC | 2 | $175 |
| EMD Serono, Inc. | 10 | $171 |
| GSK | 3 | $123 |
| Napo Pharmaceuticals Inc | 2 | $37 |
| Amarin Pharma, Inc. | 2 | $24 |
| AstraZeneca | 2 | $23 |
| Endo Pharmaceuticals Inc. | 1 | $21 |
| Nalu Medical, Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $18 |
| Novo Nordisk | 1 | $15 |
| Mylan Institutional Inc. | 1 | $14 |
| Eisai Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| Antares Pharma, Inc. | 1 | $11 |
How this compares
$471,425 in reported general payments places this provider in the 95th percentile of 146 infectious disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in Phoenix
- Robert OrensteinPhoenix$181K
- Vipul GanatraPhoenix$151K
- Ana MoranPhoenix$35K
- Adriana GaidiciPhoenix$20K
- Dwight ClarkePhoenix$18K
- Ndidiamaka ObiesiePhoenix$12K
- Ngozi OsonduPhoenix$5K
- Mirella MircescuPhoenix$4K
- Rebekah SensenigPhoenix$3K
- Edwin YuPhoenix$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.